Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

CEN Biotech Inc

Healthcare US CENBF

0.0001USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

-0.0001
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.00653M
  • Volume184
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.88985M
  • Revenue TTM1.03M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 1.03M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -1.51483M -18.94001M 14.25M -5.65512M -7.53036M
Minority interest - - - - -
Net income -1.51267M -18.90366M -9.94626M -9.25295M -7.53036M
Selling general administrative 2.25M 18.33M 2.21M 2.58M 3.10M
Selling and marketing expenses - - - - -
Gross profit 0.99M 0.63M -2.54373M -2.57981M -4.37071M
Reconciled depreciation 0.49M 0.46M 0.44M 0.44M 0.44M
Ebit -1.26484M -19.03754M 18.32M -2.57981M -3.48120M
Ebitda -0.77511M -17.60383M 18.75M -1.83837M -3.04216M
Depreciation and amortization 0.49M 1.43M 0.44M 0.74M 0.44M
Non operating income net other - - - - -
Operating income -1.26484M -19.03754M 18.32M -2.57981M -4.37071M
Other operating expenses 2.25M 18.33M 2.21M 2.58M 3.10M
Interest expense 0.25M 0.85M 3.68M 3.31M 2.87M
Tax provision 0.00000M -0.03636M - - -
Interest income 0.00061M 0.00050M 0.00640M 0.00825M 0.00940M
Net interest income -0.25215M -0.84625M -3.67046M -3.29958M -2.86162M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00216M -0.03636M 24.20M 3.60M -0.28864M
Total revenue 0.99M 0.63M 0.00000M 0.00000M 0.00000M
Total operating expenses 2.25M 18.33M 2.21M 2.58M 3.10M
Cost of revenue - - 2.54M 2.58M 4.37M
Total other income expense net -0.24999M 0.10M -4.06815M -3.07530M -1.56815M
Discontinued operations - - - - -
Net income from continuing ops -1.51483M -18.90366M 14.25M -5.65512M -7.53036M
Net income applicable to common shares - -18.90366M 14.25M -5.65512M -7.53036M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 7.86M 8.44M 6.31M 7.30M 7.31M
Intangible assets 4.78M 5.07M 4.96M 5.38M 5.81M
Earning assets - - - - -
Other current assets - 0.09M - - -
Total liab 10.15M 10.10M 16.31M 32.83M 28.58M
Total stockholder equity -2.29135M -1.65813M -9.99172M -25.53516M -21.26139M
Deferred long term liab - - - - -
Other current liab 4.53M 4.12M 3.39M 11.43M 8.21M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -47.47901M -45.96418M -27.06053M -41.31017M -35.65505M
Other liab - - 1.38M 0.72M 1.01M
Good will 1.28M 1.31M - - -
Other assets 0.00000M 1.35M 1.34M 1.53M 1.34M
Cash 0.08M 0.19M 0.00191M 0.00376M 0.00319M
Cash and equivalents - - - - -
Total current liabilities 9.97M 9.86M 14.71M 30.87M 24.41M
Current deferred revenue - - - - -
Net debt 5.14M 5.35M 11.34M 20.49M 19.15M
Short term debt 5.05M 5.30M 11.12M 19.25M 15.99M
Short long term debt 4.94M 5.20M 11.10M 19.21M 15.99M
Short long term debt total 5.23M 5.54M 11.34M 20.50M 19.15M
Other stockholder equity 45.22M 44.34M 17.07M 15.78M 14.39M
Property plant equipment - 0.24M - 0.38M 0.17M
Total current assets 0.25M 0.47M 0.02M 0.00376M 0.00319M
Long term investments - - - - -
Net tangible assets - -8.04430M -14.94786M -30.91612M -27.06716M
Short term investments - - - - -
Net receivables 0.14M 0.23M 0.02M - -
Long term debt 0.03M 0.03M 0.08M 1.06M 3.16M
Inventory - -0.03540M - - -
Accounts payable 0.40M 0.44M 0.19M 0.18M 0.21M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.03576M -0.03392M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.40M 1.34M 1.34M 1.53M 1.34M
Deferred long term asset charges - - - - -
Non current assets total 7.61M 7.97M 6.29M 7.29M 7.31M
Capital lease obligations 0.26M 0.31M 0.16M 0.23M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00994M 0.00994M -0.13010M -0.19000M -0.10544M
Change to liabilities - 0.33M 0.00584M -0.03601M 0.16M
Total cashflows from investing activities - 0.00994M -0.13010M -0.19000M -0.10544M
Net borrowings - 0.52M 0.47M 1.06M 1.75M
Total cash from financing activities 0.52M 0.52M 0.47M 1.06M 1.75M
Change to operating activities - 0.44M 3.88M 3.23M 0.11M
Net income -1.51483M -18.90366M 14.25M -5.65512M -7.53036M
Change in cash 0.19M 0.19M -0.00185M 0.00056M -0.08178M
Begin period cash flow 0.00191M 0.00191M 0.00376M 0.00319M 0.08M
End period cash flow 0.19M 0.19M 0.00191M 0.00376M 0.00319M
Total cash from operating activities -0.33550M -0.33550M -0.34075M -0.86935M -1.72400M
Issuance of capital stock - - - - -
Depreciation 0.49M 0.46M 0.44M 0.44M 0.44M
Other cashflows from investing activities - - -0.01790M -0.01790M -0.01790M
Dividends paid - - - - -
Change to inventory - 0.53M - - -
Change to account receivables 0.08M 0.01M 0.01M -0.00521M -0.19634M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 0.57M 0.57M 0.50M 1.07M 2.17M
Change to netincome - 17.18M -18.90828M 1.16M 5.08M
Capital expenditures 0.13M 0.13M 0.02M 0.02M 0.00544M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.16507M 0.84M 3.88M 0.13M 0.07M
Stock based compensation 0.55M 15.39M 0.75M 1.18M 0.68M
Other non cash items 0.30M 1.88M 1.33M 2.97M 3.44M
Free cash flow -0.46504M -0.46504M -0.34075M -0.86935M -1.72944M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CENBF
CEN Biotech Inc		 - -% 0.0001 - - 0.0063 - 6.82 -2.8736
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.

CEN Biotech Inc

3295 Quality Way, Windsor, ON, Canada, N8T 3R9

Key Executives

Name Title Year Born
Mr. Brian S. Payne CEO, CFO, VP, Sec. & Chairman 1968
Mr. Lawrence Lehoux CTO, Pres & Director 1972
Mr. Harold Andre Aubrey De Lavenu VP & Independent Director 1964
Mr. Brian S. Payne CEO, CFO, VP, Secretary & Chairman of the Board 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.